Results 31 to 40 of about 19,821,917 (190)

Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis

open access: yesJournal of Acute Disease, 2022
Thrombotic complications appear to be a major predictor of death in COVID-19 patients, and multiple studies have shown that anticoagulants can help to improve the outcome.
Adel Khalifa Sultan Hamad
doaj   +1 more source

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

open access: yesHellenic Journal of Cardiology, 2021
Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific ...
George Ntaios   +903 more
doaj   +1 more source

Safety of direct oral anticoagulants in patients with atrial fibrillation and high risk of stroke (review of literature)

open access: yesУчёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, 2020
Review discusses the problem of non-vitamin K antagonist oral anticoagulants safety in patients with non-valvular atrial fibrillation. Bleeding risk assessment while applying anticoagulant therapy, preventive methods for major bleeding (intracranial ...
E. I. Baranova   +4 more
doaj   +1 more source

Adaptation of New Oral Anticoagulants for Warfarin Anticoagulated Patient with Traumatic Ongoing Hemorrhage [PDF]

open access: yesJournal of Acute Care Surgery, 2018
The traditional drug for anticoagulation in those with a high risk of thrombosis is a vitamin K antagonist, such as warfarin. On the other hand, this drug has several limitations and hemorrhagic complications.
Jin Bong Ye   +4 more
doaj   +1 more source

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background This study aimed to compare percutaneous left atrial appendage occlusion (LAAO) with non‐vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Methods and Results Using a US administrative database, 562 850 patients
Peter A. Noseworthy   +12 more
doaj   +1 more source

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

open access: yesPLoS ONE, 2022
AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with ...
Carlos Escobar Cervantes   +10 more
doaj   +2 more sources

Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients [PDF]

open access: yes, 2021
BACKGROUND AND PURPOSE: Several observational studies have compared the effect of the non-vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation.
Dexi Wu   +15 more
core   +1 more source

Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?

open access: yesРоссийский кардиологический журнал, 2019
Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with ...
N. N. Kryukov   +3 more
doaj   +1 more source

Non-vitamin K antagonist oral anticoagulants and heart failure

open access: yesArchives of Cardiovascular Diseases, 2016
Thromboembolism contributes to morbidity and mortality in patients with heart failure (HF), and atrial fibrillation (AF) is one of the main factors promoting this complication. As they share many risk factors, HF and AF frequently coexist, and patients with both conditions are at a particularly high risk of thromboembolism.
Isnard, R.   +11 more
openaire   +3 more sources

Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants [PDF]

open access: yes, 2018
Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications.
Kozek-Langenecker, S.   +37 more
core   +2 more sources

Home - About - Disclaimer - Privacy